Myovant Sciences

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Myovant Sciences is a biotech company that develops new treatments for infertility in women and prostate cancer in men. The company's product capabilities and help continue to deliver innovative therapies addressing unmet patient needs in prostate cancer and women’s health. Myovant Sciences was established in 2016 and is based in Brisbane, California.

As Myovant overcame the odds as I forecast, Myfembree garnered another FDA approval to treat endometriosis. Subsequent to the said game-changing event, Sumitomo made an offer to acquire all outstanding shares at $22.75. However, Myovant's Board rejected the offer.

Myovant Sciences: What The Sumitomo Offer Foretells

Myovant stock has rocketed in value by >100% since my last (bearish) note on the company. The main reason for the Myovant gains is an attempt by majority shareholder Sumitomo to acquire remaining shares for $22.75 per share.

Myovant: Sumitomo Bid Is A Head Scratcher, Where Is The Value?

Myovant said "no thanks" to an acquisition offer in hopes to fetch a higher price.

Why Myovant Sciences Stock Is Skyrocketing Today

Myovant Sciences Ltd (NYSE: MYOV) opened nearly 35% up on Monday after the biopharmaceutical company said it rejected a buyout proposal from its largest shareholder. Myovant is open to considering a better offer Sumitovant Biopharma Ltd had sought to takeover the London-headquartered firm for $2.18 billion, as per the press release.

Myovant stock opened 35% up on Monday: here's the catalyst

Myovant Sciences Ltd (NYSE:MYOV) stock is soaring today, up 35.7% at $24.48 at last glance, after the biopharmaceutical name rejected a buyout offer from Japan-based Sumitomo Pharma.

Myovant Sciences Stock Skyrockets After Rejecting Buyout Offer

Myovant Sciences (NYSE: MYOV ) stock is skyrocketing over 30% today on news that the British biopharmaceutical company has received a buyout offer. MYOV stock surged as much as 31% in premarket trading after confirming media reports that it has rejected an offer from its largest shareholder, privately held Sumitovant Biopharma, to buy the shares it doesn't already own for $22.75 each.

Why Is Myovant Sciences (MYOV) Stock Up 30% Today?

Myovant Sciences turned down a takeover bid from majority shareholder Sumitovant Biopharma on Monday, and MYOV stock skyrocketed. The post Myovant Sciences Rockets After Rejecting Lowball Sumitovant Biopharma Takeover Bid appeared first on Investor's Business Daily.

Myovant Sciences Rockets After Rejecting Lowball Sumitovant Biopharma Takeover Bid

The offer came at a 27% premium to Myovant's previous market price but was below the company's trading highs last year.

Myovant Stock Soars After Rejecting $2.5 Billion Sumitomo Bid

Shares of Myovant Sciences Ltd. MYOV, +2.34% shot up 27.2% in premarket trading Monday toward an 11-month high, after the biopharmaceutical company confirmed over the weekend that it received an unsolicited buyout bid from Sumitovant Biopharma Ltd.

Myovant stock soars after confirming buyout bid, but said it 'significantly undervalues' the company

BASEL, Switzerland, Oct. 02, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences Ltd. (NYSE: MYOV) (the “Company”) confirmed today that it has received a preliminary, non-binding proposal (the “Proposal”) from Sumitovant Biopharma Ltd. (“Sumitovant”) and Sumitomo Pharma Co., Ltd. (collectively with Sumitovant, “Sumitomo”) to acquire the remaining shares of the Company that Sumitovant does not currently hold, for a price of $22.75 per share in cash. Sumitovant currently holds approximately 52% of the outstanding shares of the Company.

Myovant Sciences Special Committee of Board Confirms Receipt of Preliminary, Non-binding Proposal from Sumitovant Biopharma and Sumitomo Pharma to Acquire Remaining Shares

Pfizer

The compelling results of endometriosis treatment MYFEMBREE's phase 3 led to the drug's approval, and Myovant will be eligible for up to $200 million based on achieving certain milestones. The endometriosis market currently has few competitors, and more generally, there are many opportunities in women's health drug development.

Women Can Thank Pfizer And Myovant For MYFEMBREE

Peer Video Series Campaign and Educational Sponsorships Spotlight Patient Barriers to Conversations Peer Video Series Campaign and Educational Sponsorships Spotlight Patient Barriers to Conversations

Myovant Recognizes Prostate Cancer Awareness Month with Educational Sponsorships and Online Campaign to Encourage Patients to Speak Up, Seek Support and Be Informed

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences, a wholly owned subsidiary of Sumitovant Biopharma Ltd., receives coveted Best in Category award for an interim 12-week analysis from the ongoing Phase 2a trial of an investigational novel gene therapy product, URO-902 (plasmid human cDNA encoding maxi-K channel). The award-winning abstract was presented at the 2022 International Continence Society annual meeting on September 8, 2022. The 2022 ICS Annual meeting is being hel

Urovant Sciences® Receives “Best in Category” Award for Abstract Highlighting Investigational Novel Gene Therapy, URO-902, Presented at 2022 International Continence Society Conference

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Great Place to Work and Fortune magazine have named Urovant Sciences as one of the 2022 Best Workplaces in BioPharma. This is Urovant's first time being named to this prestigious list, this year coming in at 17th place. Earning a spot means that Urovant is one of the best biopharma companies to work for in the country. The Best Workplaces in BioPharma award is based on analysis of survey responses from more than 36,000 employees from Great P

Urovant Sciences® Named 17th on the List of Fortune® Best Workplaces in BioPharma™ (2022)

BASEL, Switzerland, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, today announced that David Marek, Chief Executive Officer of Myovant Sciences, Inc., and Uneek Mehra, Chief Financial and Business Officer, will participate in the following upcoming investor conferences:

Myovant Sciences to Participate at Upcoming Investor Conferences

Myovant secured FDA approval for Myfembree for the treatment of endometriosis in early August. The approval clears the regulatory overhang on the stock but now comes the harder part - commercialization of Myfembree in this indication.

Myovant Sciences: Regulatory Overhang Cleared

BASEL, Switzerland and NEW YORK, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved MYFEMBREE® (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) as a one-pill, once-a-day therapy for the management of moderate to severe pain associated with endometriosis in pre-menopausal women, with a treatment duration of up to 24 months. The approval is supported by one-year efficacy and safety data, including 24-week data from the Phase 3 SPIRIT 1 and SPIRIT 2 trials, which were published in The Lancet, and the first 28 weeks of an open-label extension study for eligible women who completed either SPIRIT 1 or SPIRIT 2. MYFEMBREE also is approved for heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Myovant and Pfizer will continue to jointly commercialize MYFEMBREE in the U.S. and product is available immediately.

Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis

Myovant Sciences Ltd. (NYSE:MYOV ) Q1 2022 Results Conference Call July 27, 2022 5:00 PM ET Company Participants Uneek Mehra - Chief Financial & Business Officer Dave Marek - Chief Executive Officer Lauren Merendino - Chief Commercial Officer Dr. Juan Camilo Arjona - Chief Medical Officer Conference Call Participants Phil Nadeau - Cowen Brian Skorney - Baird Eric Joseph - JPMorgan Madhu Kumar - Goldman Sachs Roanna Ruiz - SVB Securities Gavin Clark-Gartner - Evercore ISI Operator Good day, everyone and welcome to Myovant Sciences' First Quarter Fiscal Year 2022 Earnings Conference Call.

Myovant Sciences Ltd. (MYOV) CEO Dave Marek on Q1 2022 Results - Earnings Call Transcript

Myovant Sciences (MYOV) delivered earnings and revenue surprises of -69.23% and 8.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Myovant Sciences (MYOV) Reports Q1 Loss, Tops Revenue Estimates

BASEL, Switzerland, July 27, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, today announced financial results for the first quarter of fiscal year 2022 and provided other corporate updates.

Myovant Sciences Announces Corporate Updates and Financial Results for First Fiscal Quarter 2022

Myovant has performed well since the regulatory setback in April. The PDUFA date for the sNDA for Myfembree has been extended by three months and Orgovyx was approved in Europe.

Myovant Makes Commercial Progress As It Waits For FDA Decision On Myfembree

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., today announced the peer-reviewed journal publication of the findings from a survey of Directors of Nursing (DONs) in U.S. long-term care settings. The results highlight the need for improved awareness, education, and management of urinary incontinence (UI) related to overactive bladder (OAB) in the long-term care population. The paper is titled “Impact of Urinary Inco

The Impact of Urinary Incontinence Related to Overactive Bladder on Long-Term Care Residents and Facilities in the U.S. Highlighted in New Survey

BASEL, Switzerland, July 13, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), today announced it will host a webcast and conference call to discuss corporate updates and financial results for its first fiscal quarter, ended June 30, 2022. The webcast and conference call will be held at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on July 27, 2022.

Myovant Sciences to Host First Fiscal Quarter 2022 Earnings Conference Call at 5:00 p.m. Eastern Time on July 27, 2022

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., has been named for the 2nd year in a row as one of the Best Places to Work by the Orange County Business Journal. “It's an honor to be recognized as a Best Place to Work not once, but twice by the Business Journal,” said James Robinson, CEO of Urovant Sciences. “Because the list is largely based on responses from our colleagues, we feel this honor celebrates our deeply

Urovant Sciences® Named One of 2022 “Best Places to Work” in Orange County

BASEL, Switzerland, & CASTRES, France--(BUSINESS WIRE)--Urovant Sciences & Pierre Fabre Médicament Enter Exclusive License Agreement to Commercialize Vibegron in European Economic Area, UK, Switzerland

Urovant Sciences and Pierre Fabre Médicament Enter into Exclusive License Agreement to Commercialize Vibegron for the Treatment of Overactive Bladder in the European Economic Area, UK, and Switzerland

News for Myovant Sciences Stock (MYOV)